Zoetis (NYSE:ZTS) is a leading global animal health company dedicated to the discovery, development, manufacturing and commercialization of innovative medicines, vaccines and diagnostic products for livestock and companion animals. Headquartered in Parsippany, New Jersey, Zoetis serves veterinarians, livestock producers and pet owners in more than 100 countries, offering a diverse portfolio designed to improve animal health and productivity.
The company’s core business activities encompass pharmaceuticals, vaccines, parasiticides and therapeutic proteins, as well as a growing suite of diagnostic instruments and consumables. Zoetis also provides digital solutions and services to help customers optimize herd management, enhance disease surveillance and support data-driven veterinary decision-making. Its R&D efforts focus on addressing emerging health challenges, antimicrobial resistance and unmet needs in both food-producing and companion animal sectors.
Since its spin-off from Pfizer in 2013, Zoetis has expanded its global footprint through strategic acquisitions, partnerships and the establishment of research centers in North America, Europe, Latin America and Asia Pacific. This international reach enables the company to tailor products and educational programs to diverse regulatory environments, farming practices and pet care trends around the world.
Under the leadership of President and Chief Executive Officer Kristin Peck, Zoetis emphasizes a culture of innovation, sustainability and corporate responsibility. The company maintains a strong commitment to animal welfare, environmental stewardship and the advancement of veterinary science, while fostering collaborative relationships with industry stakeholders, academia and nonprofit organizations.
